论文部分内容阅读
目的系统评价益气养阴中药治疗中晚期非小细胞肺癌的疗效及安全性。方法计算机检索中国生物医学文献数据库、中国学术期刊全文数据库、维普知识资源系统、Pubmed、Cochrane图书馆数据库,自建库至2016年1月发表的关于益气养阴中药治疗非小细胞肺癌的临床随机对照研究文献,利用Rev Man5.0软件对同质研究合并进行Meta分析,运用Cochrane Reviewer’s Handbook5.0.1评价标准进行质量评价。结果最终纳入17项研究,1 123例受试者。Meta分析结果表明使用益气养阴中药联合化疗的试验组在近期有效率、生存质量、中医症状改善及抑制白细胞及血小板下降和恶心呕吐等不良反应方面均优于单纯使用化疗的对照组。结论益气养阴中药治疗中晚期非小细胞肺癌具有良好的安全性,疗效确切。
Objective To evaluate the efficacy and safety of Yiqi Yangyin Chinese herbs in the treatment of advanced non-small cell lung cancer. Methods A computer-based online search of China Biomedical Literature Database, Chinese Academic Journal Full-text Database, VIP Information Resource System, PubMed, Cochrane Library Database, and self-built database was conducted in January 2016 to discuss clinical trials of Yiqi Yangyin Chinese medicine in the treatment of non-small cell lung cancer Randomized controlled studies were conducted using Meta-analysis of homogenous studies using Rev Man 5.0 software and quality assessment using the Cochrane Reviewer’s Handbook 5.0.1 evaluation criteria. The results eventually included 17 studies and 1 123 subjects. The results of Meta-analysis showed that the experimental group treated with Yiqi Yangyin combined with chemotherapy was better than the chemotherapy-only control group in terms of the recent efficacy, quality of life, improvement of symptoms of Chinese medicine, and the suppression of adverse reactions such as leucocyte and thrombocytopenia and nausea and vomiting. Conclusion Yiqi Yangyin Chinese medicine treatment of advanced non-small cell lung cancer has good safety, curative effect.